Davis HL - Search Results

1

Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.

Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM. Vollmer J, et al. Among authors: davis hl. J Leukoc Biol. 2004 Sep;76(3):585-93. doi: 10.1189/jlb.0104034. Epub 2004 Jun 24. J Leukoc Biol. 2004. PMID: 15218053

2

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Vollmer J, et al. Among authors: davis hl. Eur J Immunol. 2004 Jan;34(1):251-62. doi: 10.1002/eji.200324032. Eur J Immunol. 2004. PMID: 14971051 Free article.

3

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM. Vollmer J, et al. Among authors: davis hl. Immunology. 2004 Oct;113(2):212-23. doi: 10.1111/j.1365-2567.2004.01962.x. Immunology. 2004. PMID: 15379982 Free PMC article.

4

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85. doi: 10.1111/j.1574-695X.2002.tb00551.x. FEMS Immunol Med Microbiol. 2002. PMID: 11934561 Free article.

5

CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice.

Weeratna R, Comanita L, Davis HL. Weeratna R, et al. Among authors: davis hl. Immunol Cell Biol. 2003 Feb;81(1):59-62. doi: 10.1046/j.1440-1711.2003.01135.x. Immunol Cell Biol. 2003. PMID: 12534947

6

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.

Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Krieg AM, et al. Among authors: davis hl. J Immunother. 2004 Nov-Dec;27(6):460-71. doi: 10.1097/00002371-200411000-00006. J Immunother. 2004. PMID: 15534490 Clinical Trial.

7

Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.

Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E. Noll BO, et al. Among authors: davis hl. Biochem Pharmacol. 2005 Mar 15;69(6):981-91. doi: 10.1016/j.bcp.2004.12.013. Biochem Pharmacol. 2005. PMID: 15748709

8

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. Weeratna RD, et al. Among authors: davis hl. Vaccine. 2005 Nov 1;23(45):5263-70. doi: 10.1016/j.vaccine.2005.06.024. Epub 2005 Jul 18. Vaccine. 2005. PMID: 16081189

9

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

McCluskie MJ, Cartier JL, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Antiviral Res. 2006 Feb;69(2):77-85. doi: 10.1016/j.antiviral.2005.10.007. Epub 2005 Dec 5. Antiviral Res. 2006. PMID: 16377001

10

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.

Cooper CL, Ahluwalia NK, Efler SM, Vollmer J, Krieg AM, Davis HL. Cooper CL, et al. Among authors: davis hl. J Immune Based Ther Vaccines. 2008 Jun 9;6:3. doi: 10.1186/1476-8518-6-3. J Immune Based Ther Vaccines. 2008. PMID: 18541039 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters